New Single-Pill HIV Treatment Approved for People Existing Options Left Behind

Bixlenvo is the first once-daily tablet designed for the 81% of people whose virus developed resistance to standard regimens.

Told by Claire Lawson · 2 September 2026

There's a new pill for people living with HIV, and for once the word 'new' actually means something.

The U.S. Food and Drug Administration approved Bixlenvo on August 27, 2026 — a once-daily single tablet combining bictegravir 75mg with lenacapavir 50mg, made by Gilead Sciences. It's indicated for adults whose virus is already suppressed but who can't take the existing single-tablet regimens because their virus developed resistance or the side effects were intolerable. That's not a small group. It's most people on complex regimens.

Here's what the approval actually says, in the language regulators use when they mean it:

Bixlenvo is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of Bixlenvo.

Translation: if you're undetectable, and your current pills are working but you're taking a handful of them twice a day because nothing simpler has worked for you, this is the first single tablet designed for you. Not adapted. Designed.

The ARTISTRY-1 trial that got this approved enrolled the oldest study population in a Phase 3 HIV treatment trial to date — median age 60. These weren't people starting treatment yesterday. Median treatment duration was 28 years. They were taking between two and 11 pills a day at baseline, and 40% were dosing more than once daily. Sixty-seven per cent had NRTI resistance. Eighty-one per cent were on a complex regimen because of antiretroviral resistance, not in spite of it.

Those are the people this pill is for.

Bictegravir is a guideline-recommended integrase inhibitor with a high barrier to resistance — it's already in Biktarvy, which many people take. Lenacapavir is newer: a first-in-class capsid inhibitor that works at multiple stages of the HIV life cycle and has no cross-resistance to other antiretrovirals. That last bit matters. If your virus has figured out how to get around one class of drugs, lenacapavir doesn't care — it's attacking a different part of the process entirely.

At Week 48, Bixlenvo maintained virologic suppression and was generally well tolerated. The most common adverse reactions were headache (4%), nausea (3%), and diarrhea (2%). Switching from complex regimens to Bixlenvo was associated with improvements in certain fasting lipid parameters and participant-reported treatment satisfaction. ARTISTRY-2 showed switching to Bixlenvo had no significant impact on weight.

There's a two-day initiation: Bixlenvo plus two tablets of Sunlenca (lenacapavir) on Day 1, same again on Day 2, then just Bixlenvo once daily from Day 3 onward. If you miss the maintenance dose and more than seven days pass, you start the initiation again — assuming it's still clinically appropriate.

Bixlenvo is only approved in the United States. It's the smallest single-tablet regimen available, and Gilead says it's the first of what they hope will be many in a pipeline that includes daily, weekly and longer-acting options.

For people who've been managing HIV for decades — people who were on AZT monotherapy, who survived the combination therapy lottery, who've watched their regimens get simpler for everyone except them — this is the option that finally remembers they exist.